ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-PO1046

Safety and Impact of Low Protein Diet and Ketosteril Before ESRD

Session Information

Category: Health Maintenance, Nutrition, and Metabolism

  • 1302 Health Maintenance, Nutrition, and Metabolism: Clinical

Author

  • Chang, Chih-Hsiang, Chang Gung Memorial Hospital, Taoyuan, Taiwan
Background

Low protein diet with ketoacid analogue supplement (LPD-KA) remained under employed in patients with chronic kidney disease (CKD) because of safety issue and low compliance. This study aims to evaluate the sepsis and cardiovascular outcome in patient who received LPD-KA before end stage kidney disease (ESKD).

Methods

The study analyzed encrypted datasets from Taiwan’s National Health Insurance Research Database. The exposure group was the patients received LPD and ketoacid analogue over 6 months before ESKD and the comparison group was patients who did not received LPD. Outcomes included mortality cardiovascular event, sepsis and in follow up.

Results

The data of 2607 patients in the LPD group and 10428 propensity score matched patients without LPD between January 1, 2001 and December 31, 2013 were analyzed. Patients on LPD-KA had lower mortality (23.1% vs. 27.6%; hazard ratio [HR] 0.77, 95% confidence interval [CI] 0.70-0.84), lower composite cardiovascular events (19.2% vs. 21.5%; HR 0.86, 95% CI 0.78-0.94), and sepsis death (6.6% vs. 8.5%; HR 0.74, 95% CI 0.63-0.87).

Conclusion

LPD might be a safe therapy for patient of CKD. Overall mortality, cardiovascular event and sepsis death are less in LPD-KA group.